Is Merck Stock a Top Buy Right Now? | The Motley Fool
The drugmaker is still a work in progress.
Stay updated with breaking news from Acceleron Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The drugmaker is still a work in progress.
Not every familiar name is a company you can comfortably tuck away in your portfolio for decades, but these two are.
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) (the Company) today issued a letter to its shareholders in connection with the Company's upcoming 2023 Annual...
Sarissa's Proposed Candidates Would Not Bring New Skills to the Board Recommends Shareholders Vote "FOR" Alkermes' Director Nominees on Company's WHITE Proxy Card DUBLIN, June 13,
Treatment with luspatercept vs. epoetin alfa nearly doubled the number of patients with lower-risk myelodysplastic syndrome who no longer required red blood cell transfusions for anemia, results of the phase 3 COMMANDS trial showed.The findings, scheduled for presentation at ASCO Annual Meeting, showed luspatercept (Reblozyl; Celgene, Bristol Myers Squibb) — an erythroid maturation agent